2 nd Quarter 2009 Results

Size: px
Start display at page:

Download "2 nd Quarter 2009 Results"

Transcription

1 2 nd Quarter 2009 Results Dr. Michael Becker General Partner and Chief Financial Officer Elmar Schnee General Partner and Member of the Executive Board, Head of Pharmaceuticals July 24, 2009

2 Disclaimer Remarks All comparative figures relate to the corresponding last year s period. From 2007 the Generics business is reported in discontinued operations. With the divestiture of Electronic Chemicals in Q this division and the remaining toll manufacturing business are allocated to Corporate & Other. Return on Sales (ROS) calculation is based on total revenues. Important Information This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in the United States. The shares referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act ), and may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from such registration. Note regarding forward-looking statements The information in this document may contain forward-looking statements. Forward-looking statements may be identified by words such as expects, anticipates, intends, plans, believes, seeks, estimates, will or words of similar meaning and include, but are not limited to, statements about the expected future business of Merck KGaA resulting from the proposed transaction. These statements are based on the current expectations of management of Merck KGaA and E. Merck KG, and are inherently subject to uncertainties and changes in circumstances. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are factors relating to satisfaction of the conditions to the proposed transaction, and changes in global, political, economic, business, competitive, market and regulatory forces. Merck KGaA and E. Merck KG do not undertake any obligation to update the forward-looking statements to reflect actual results, or any change in events, conditions, assumptions or other factors. Page 2

3 Table Of Contents 1 Merck Executive Summary and Business Strategies 2 Group Financial Details 3 Divisional Developments 4 Outlook Page 3

4 Merck Group Business Strategies Merck Serono Focus on innovative, specialist drugs in prescription markets Build therapeutic core areas, seize opportunities in emerging fields Strengthen leading market positions in established areas Improve R&D efficiency and leverage biopharmaceutical expertise Consumer Health Care Focus on over-the-counter pharma products in four health themes Grow key brands through regional expansion Strengthen business in established markets Liquid Crystals Focus on innovation in display technologies to sustain market leadership Capitalize on excellent reputation in quality and reliability Broaden application basis long-term with penetration into new markets Performance & Life Science Chemicals Focus on specialty chemicals solutions Leverage strong expertise in regulated markets with high entry barriers Strengthen position in growth focus regions: India and China [ 1 ] Merck - Executive Summary and Business Strategies Page 4

5 Merck Group Q Progress in Strategy Merck Serono Development of potentially first oral MS drug cladribine tablets progressing: Positive Phase III results announced at AAN and ENS Marketing authorization application filed with EMEA in July Start of additional Phase III trials in Parkinson s Disease and breast cancer Consumer Health Care 6 out of 7 strategic brands organically growing Ongoing investments into R&D as well as Marketing & Selling Liquid Crystals Customer migration to new technology PS-VA progressing Technology leadership supported by ongoing investments into R&D Performance & Life Science Chemicals Successful continuation of business expansion in India Launch of new solutions for regulated markets [ 1 ] Merck - Executive Summary and Business Strategies Page 5

6 Merck Group Q Group Key Financials m Total Revenues Sales Core Operating Result *) Core ROS (Core Return on Revenues) Core EPS **) in Q , , % 1.10 Q , , % 1.53 Δ in % Exceptionals - - Free Cash Flow (before acquisitions and divestitures) Underlying Tax Rate (excl. Exceptionals) 25.9% 26.5% Net Financial Debt (as of June 30) * Core Operating Result = Operating Result less costs related to the purchase of Serono (amortization and impairments of intangible assets, and integration costs) and excl. Generics. ** Core EPS = EPS from continuing operations less costs related to the purchase of Serono (amortization and impairments of intangible assets, and integration costs) and exceptionals and excl. Generics. [ 1 ] Merck - Executive Summary and Business Strategies Page 6

7 Merck Group Q by Division Revenues by Division m Operating Result by Division m +6.0% 1,237 1,312 Q Q % % % 107 Q Q % % % % Merck Serono Consumer Health Care Liquid Crystals Performance & Life Science Chemicals Merck Serono* * Core Operating Result Consumer Health Care Liquid Crystals Performance & Life Science Chemicals [ 2 ] Group Financial Details Page 7

8 Merck Group Q Revenue Growth Analysis Nominal Organic Currency Acquisitions/ Divestitures Merck Serono 6.0% 4.7% 1.3% 0.0% Consumer Health Care -2.7% -0.3% -4.1% 1.8% Liquid Crystals -20.6% -21.3% 0.6% 0.1% Performance & Life Science Chemicals -7.5% -9.5% 2.0% 0.0% Merck Group -0.1% -1.3% 1.0% 0.1% [ 2 ] Group Financial Details Page 8

9 Merck Group Key Balance Sheet Data m Jun. 30, 2009 in % of total assets Dec. 31, 2008 Total Assets 16, ,645 Equity 9, ,563 Cash and Financial Debt up following 750m bond in March Cash Intangible Assets 7, ,203 Financial Debt 2, ,346 Pension Provisions 1, ,144 Net Financial Debt [ 2 ] Group Financial Details Page 9

10 Merck Group Key Cash Flow Data m Q Q Δ Profit After Tax Depreciation/Amortization Changes in Working Capital Capital Expenditures Other Free Cash Flow Free Cash Flow (before acquisitions and divestitures) [ 2 ] Group Financial Details Page 10

11 Merck Serono Key Financials m Q Q Δ in % Total Revenues 1, , Sales 1, , Marketing & Selling Research & Development Core Operating Result * Core ROS (Return on Revenues) 20.7% 26.3% Free Cash Flow (before acquisitions and divestitures) Organic revenue growth +4.7%; additional +1.3% tailwind from FX Royalty income down 15% to 70m Marketing & selling up due to increased commission expenses as well as product launches (Kuvan, RebiSmart) and pre-launches (cladribine tablets) Higher R&D investments driven by new study starts and increasingly maturing pipeline Strong free cash flow mainly due to lower changes in working capital (oneoff in 2008: factoring in Italy stopped in Q2 2008) * Core Operating Result = Operating Result less costs related to the purchase of Serono (amortization and impairments of intangible assets, and integration costs) and excl. Generics. [ 3 ] Divisional Developments Page 11

12 Merck Serono Operational Developments Sales by Therapeutic Area m Neurodegen. Diseases Oncology AIID Fertility Endocrinology CMC/local Rebif Er bitux Gonal-f Concor Glucophage % % +16% Q Q Sales by Top 5 Products m % -6.6% -3.1% +18% +21% +21% +3.7% Q Q Rebif with continued strong growth: 11% in Europe 45% in the USA driven by higher volumes, favorable pricing environment and positive FX impacts Erbitux performance driven by: increasing penetration in 1 st line mcrc and recurrent/metastatic head&neck cancer further growth from 2 nd /3 rd line mcrc usage in countries without 1 st line approval Market withdrawal of Raptiva (AIID) ongoing Revenues in Fertility stable softer Gonal-f sales partially offset by better Pergoveris performance Strong growth in Endocrinology benefiting from double digit growth from Saizen and market launch of Kuvan [ 3 ] Divisional Developments Page 12

13 Merck Serono NDD Developments since Q Rebif Introduction of RebiSmart in June, the first electronic injection device in MS offering improved ease of usage and potential for improved treatment adherence Cladribine Tablets: Potentially the 1 st oral MS treatment Results from CLARITY study presented at AAN in April and ENS in June: Primary endpoint met: reduction in annualized relapse rate > 50% vs. placebo All key secondary endpoints met ~90% of patients completed treatment in each group, indicating overall a favourable tolerability Frequencies of adverse events comparable between treatment and placebo groups - Observed malignancies were isolated cases across different organ systems Marketing authorization application submitted to EMEA in July Safinamide Results from Study 016 presented at MDS in June Primary and secondary efficacy endpoints met significant improvement of motor symptoms by increasing ON time [ 3 ] Divisional Developments Page 13

14 Merck Serono Oncology Developments since Q Erbitux NICE: positive recommendation for 1 st line use in mcrc patients with KRAS wild-type tumors and liver limited disease; Erbitux is the only targeted therapy endorsed by NICE for mcrc treatment ASCO 2009: Personalizing cancer care in line with Merck Serono s strategy in oncology now approved for mcrc in 76 countries (Brazil added in Q2), for SCCHN in 71 countries Cilengitide Merck Erbitux Sales m ASCO 2009: increased overall survival in 1 st line glioblastoma patients in a randomized Phase II study Stimuvax Initiation of Phase III study (STRIDE) with Stimuvax added to hormone therapy in advanced breast cancer ASCO 2009: long-term safety in advanced NSCLC patients receiving treatment for up to 8.2 years in randomized Phase II trial 145 Q Q % 141 Q Q Q [ 3 ] Divisional Developments Page 14

15 Merck Serono Pipeline Development since Q Topic Gonal-f approval for ovulation induction in infertile woman in Japan Detailed Phase III study data (CLARITY) from cladribine tablets in relapsing MS Submission of dossier for cladribine tablets in relapsing MS in EU Submission of dossier for Tesamorelin in HIV patients with lipodystrophy in the USA Detailed Phase III study data (Study 016) from safinamide + levodopa in advanced PD Inititation of Phase III study (SETTLE) to evaluate safinamide + levodopa in mid- to late-stage PD Inititation of Phase III study (STRIDE) to evaluate Stimuvax in breast cancer Target not disclosed Q2 mid of 2009 not disclosed Apr.-Jul not disclosed not disclosed Timeline Delivery Q3 Q2 Q3 Q2 Q2 Q2 Q2 [ 3 ] Divisional Developments Page 15

16 Merck Serono Pipeline Portfolio as per July 24, 2009 Phase I Phase II Phase III in Registration Aurora Kinase Inhibitor (AS703569) Solid tumors and hematological malignancies NHS-IL2-LT, immunocytokine Solid tumors DI17E6, integrin inhibitor, antiangiogenic Solid tumors Eg 5 inhibitor Solid tumors and hematological malignancies Survivac, therapeutic cancer vaccine Solid tumors MEK Inhibitor (AS703026) Solid tumors IMO-2055, TLR9 immunomodulator Solid tumors Sonepcizumab (ASONEP TM )anti- S1P monocolnal antibody Solid tumors Fibroblast Growth Factor 18 Osteoarthritis Atacicept, anti-blys/anti-april fusion protein Multiple Sclerosis Erbitux (cetuximab) Breast cancer Tucotuzumab celmoleukin, huks-il2, immunocytokine Small cell lung cancer (SCLC) Cilengitide, integrin inhibitor, anti-angiogenic SCCHN Cilengitide, integrin inhibitor, anti-angiogenic NSCLC Adecatumumab, anti-epcam monoclonal antibody Colorectal Cancer Atacicept, anti-blys/anti-april fusion protein Rheumatoid Arthritis ARX 201, long acting GH Growth hormone deficiencies Rebif New Formulation in CIS (REFLEX) Cladribine tablets in CIS (ORACLE) Safinamide (MOTION) Early stage Parkinson s Safinamide (SETTLE) Mid-to-late stage Parkinson s Erbitux (cetuximab) (PETACC-8*) Adj Colon Cancer Erbitux (cetuximab) (EXPAND) Gastric Cancer Cilengitide, integrin inhibitor, anti-angiogenic (CENTRIC) Glioblastoma Stimuvax, therapeutic cancer vaccine (START) NSCLC Stimuvax, therapeutic cancer vaccine (STRIDE) Breast Cancer Atacicept, anti-blys/anti-april fusion protein (APRIL SLE) Lupus Rebif New Formulation Relapsing forms of MS FDA: Submission filed Cladribine tablets Relapsing forms of MS EMEA: Submission filed FDA: Submission to be filed in Q3 09 Erbitux (cetuximab) NSCLC 1 st line therapy EMEA: Submission filed Tesamorelin HIV patients with lipodystrophy (US only) Oncology Neurodegenerative Diseases Autoimmune & Inflammatory Diseases Endocrinology *Sponsored and coordinated by the Fédération Francophone de Cancérologie Digestive (FFCD) Appendix Page 16

17 Merck Serono Pipeline Catalysts 12 Months Rolling CHMP opinion for Erbitux in 1 st line NSCLC US filing cladribine tablets in relapsing MS Q1-Q3: Phase III data from Rebif in CIS (REFLEX) Q2/Q3: FDA Action Letter expected for cladribine tablets in relapsing MS Completion of Phase II studies for atacicept Oncology Neurodegenerative Diseases Autoimmune & Inflammatory Diseases Endocrinology Q Q4 Q Q2 [ 3 ] Divisional Developments Page 17

18 Consumer Health Care Key Financials m Q Q Δ in % Total Revenues Marketing & Selling Research & Development Operating Result Organic revenue growth -0.3%, FX impact of -4.1% Drop in operating result influenced by 4m base line effect from settlement with raw material supplier in Q Free cash flow impacted by favourable working capital development ROS (Return on Revenues) 10.0% 14.3% Free Cash Flow (before acquisitions and divestitures) [ 3 ] Divisional Developments Page 18

19 Consumer Health Care Operational Developments Sales by Health Theme m Mobility Woman's and Children's Health Everyday protection Cough & Cold % % % Q Q % Development of strategic brands: organic growth of 5%, especially boosted by Femibion (+12%; Launch in Spain and good development in Poland) Cebion (+29%, in particular Venezuela) and Diabion (+112%, driven by Mexico) now contributing to >50% of the total business (excl. Mailorder) Others % [ 3 ] Divisional Developments Page 19

20 Liquid Crystals Key Financials m Q Q Δ in % Total Revenues Marketing & Selling R&D Operating Result ROS (Return on Revenues) 27.4% 45.0% Free Cash Flow (before acquisitions and divestitures) Business continued to pick up Organic revenues down 21%; FX impact negligible Increasing investments into R&D Operating result recovered significantly from low in Q1 due to higher capacity utilization and favourable product mix Improved inventory management partly offsets the impact of reduced operating result on free cash flow [ 3 ] Divisional Developments Page 20

21 Liquid Crystals Business Dynamics Industry comments for Q3 encouraging Ongoing price pressure Merck s exclusive technology PS-VA gaining further market share [ 3 ] Divisional Developments Page 21

22 Performance & Life Science Chemicals Key Financials m Q Q Δ in % Total Revenues Marketing & Selling R&D Operating Result ROS (Return on Revenues) 6.0% 12.4% Free Cash Flow (before acquisitions and divestitures) Organic revenue growth -9.5%, dampened by +2.0% tailwind from FX Weak demand from automotive and cosmetics industries continued Solid Laboratory business, resisting weak global economy Operating result mainly impacted by softer sales and lower capacity utilization in Pigments Strong free cash flow driven by improvements in working capital management [ 3 ] Divisional Developments Page 22

23 Performance & Life Science Chemicals Operational Developments Sales by Region m Europe % Q Q Ongoing weakness in Pigments weighed on Europe sales Business in North America benefitting from favourable FX development and Crop Bioscience business North America % Asia: Strong growth in India and Life Science Solutions business Latin America % Asia % Rest of World % [ 3 ] Divisional Developments Page 23

24 Merck Group Outlook Update FY2009 Outlook FY 2009 Revenues* Actual H Revenues* Outlook FY 2009 ROS Actual H ROS Merck Serono Consumer Health Care Liquid Crystals Performance & Life Science Chemicals + 6-9% + 8.4% 20-25%** 22.6% ** + 3-6% (old: + 5-9%) 20-25% (old: 20-30%) 2.8% 32% 5-10% 20-30% 8.6% 20.1% unchanged 6.9% 5-10% 7.0% Corporate & Others Operating Result unchanged (H1 2009: 7.0%) Merck Group + 0-5% 0.1% 15-20%** 18.0%** * Compared to 2008 ** Core ROS [ 4 ] Outlook Page 24

25 Investor Relations Events DATE EVENT Oct 26, 2009 Publication of business results for Q Conference Call More details can be found on: Page 25

26 Investor Relations Your Contact Dr. Thomas Kornek Claudia Nickolaus Alessandra Heinz Assistant Investor Relations Merck KGaA Investor Relations Frankfurter Str Darmstadt Germany Fax: Page 26

27 2 nd Quarter 2009 Appendix >> Page 27

28 Merck Group Reconciliation to Core Figures Core Operating Result ( million) Q Q Δ in % Operating Result (excl. Generics) Amortization of Intangibles Impairments of Serono Intangible Assets Following PPA Restructuring/Special Integration Costs Serono Core Operating Result Core Earnings Per Share ( million) Q Q Δ in % Net Income (Continuing Operations excl. Generics) Amortization of Intangibles 1 Impairments of Serono Intangible Assets Following PPA Restructuring/Special Integration Costs Serono Exceptionals./. Tax Adjustments Core Net income Core EPS Only Merck Serono assets are considered. 2 According to IAS 33 EPS is calculated on the average weighted number of shares (Q2 2009: m; Q2 2008: 217.4m). Appendix Page 28

29 Merck Group Income Statement million Q Q Δ in % Sales 1, , Royalty Income Total Revenues 1, , SG&A R&D Amortization of Intangibles Operating Result Exceptionals - - EBIT Financial Result Profit Before Tax Income Tax Profit After Tax (Continuing Operations) Profit After Tax (Discontinued Operations) Minorities Net Income Earnings Per Share ( ) 1 Reported According to IAS 33 EPS is calculated on the average weighted number of shares (Q2 2009: 217.4m; Q2 2008: 217.4m). Appendix Page 29

30 Merck Group Costs million Q Q Δ in % Sales 1, , Royalty Income Total Revenues 1, , Cost of Sales Gross Margin 1, , Marketing & Selling Administration Other Expenses/Income R & D Amortization of Intangible Assets All Others Operating Result Appendix Page 30

31 Merck Group Administration Expenses m Q Q Q Q Q Q Appendix Page 31

32 Financial Figures Detailed figure sheet available for direct download: Appendix Page 32

Business Review and Results Presentation Full Year 2007

Business Review and Results Presentation Full Year 2007 Business Review and Results Presentation Full Year 2007 Dr. Karl-Ludwig Kley (Chairman of the Executive Board), Dr. Michael Becker (CFO) February 18 th, 2008 Disclaimer Remarks All comparative figures

More information

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple

More information

4 th Quarter and Full Year 2009 Results

4 th Quarter and Full Year 2009 Results 4 th Quarter and Full Year 2009 Results Dr. Karl-Ludwig Kley General Partner and Chairman of the Executive Board Dr. Michael Becker General Partner and Member of the Executive Board, Chief Financial Officer

More information

Merck Interim Report Q3 2013

Merck Interim Report Q3 2013 Merck Interim Report Q3 2013 Interim Report Q3, 2013 2 Contents Interim Management Report as of September 30, 2013 03 The Merck Group 03 Highlights 08 Divisions 09 Merck Serono 15 Consumer Health 17 Performance

More information

Focus on fleet customers SAF-HOLLAND Annual Financial Statements 2013

Focus on fleet customers SAF-HOLLAND Annual Financial Statements 2013 Focus on fleet customers SAF-HOLLAND Annual Financial Statements 213 Detlef Borghardt, CEO Wilfried Trepels, CFO March 13, 214 Agenda 1 Financials 3 2 Appendix 21 2 Executive Summary 1 2 3 Group sales

More information

SAF-HOLLAND Annual Financial Statements 2012. Detlef Borghardt, CEO Wilfried Trepels, CFO. March 14, 2013

SAF-HOLLAND Annual Financial Statements 2012. Detlef Borghardt, CEO Wilfried Trepels, CFO. March 14, 2013 SAF-HOLLAND Annual Financial Statements 212 Detlef Borghardt, CEO Wilfried Trepels, CFO March 14, 213 Executive Summary business volume successfully expanded in 212 1 Group sales increased yoy by 3.4%

More information

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015 Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future

More information

Ludwigshafen, February 25, 2014

Ludwigshafen, February 25, 2014 Ludwigshafen, February 25, 2014 Analyst Conference FY2013 Cautionary note regarding forward-looking statements This presentation may contain forward-looking statements that are subject to risks and uncertainties,

More information

Q1/2015 Results VTG AG Connecting worlds. Dr. Heiko Fischer, CEO Dr. Kai Kleeberg, CFO May 21, 2015

Q1/2015 Results VTG AG Connecting worlds. Dr. Heiko Fischer, CEO Dr. Kai Kleeberg, CFO May 21, 2015 Q1/2015 Results VTG AG Connecting worlds Dr. Heiko Fischer, CEO Dr. Kai Kleeberg, CFO May 21, 2015 Table of content 1 Discussion of Q1/2015 2 Outlook FY 2015 3 Questions & Answers 4 Financial Calendar

More information

Procter & Gamble Earnings Release: Q3 FY 2016 Results. April 26, 2016

Procter & Gamble Earnings Release: Q3 FY 2016 Results. April 26, 2016 Procter & Gamble Earnings Release: Q3 FY 2016 Results April 26, 2016 Business Results Q3 FY 2016 Jan Mar 16 (Q3 FY 16) Results Organic Sales Growth* 3% 2% 2% 1% 1% 1% 1% 0% -1% -1% JFM 15 AMJ 15 JAS 15

More information

Dr. Reddy s Q3 and 9M FY16 Financial Results

Dr. Reddy s Q3 and 9M FY16 Financial Results Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CONTACT

More information

Regal Beloit Corporation Second Quarter 2014 Earnings Conference Call

Regal Beloit Corporation Second Quarter 2014 Earnings Conference Call Regal Beloit Corporation Second Quarter 2014 Earnings Conference Call July 30, 2014 Mark Gliebe Chairman and Chief Executive Officer Jon Schlemmer Chief Operating Officer Chuck Hinrichs Vice President

More information

MOLOGEN AG German Equity Forum 2015

MOLOGEN AG German Equity Forum 2015 German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies

More information

Full Year Results 2014

Full Year Results 2014 Full Year Results 2014 18 March 2015 Conference call on FY Results 2014 Corporate Finance & Investor Relations AGENDA FY 2014 results presentation Highlights 2014 Financials 2014 Outlook 2015 Appendix

More information

FINANCIAL RESULTS Q4/2015 & 2015 ESA TIHILÄ, CEO NICLAS ROSENLEW, CFO FEBRUARY 2, 2016

FINANCIAL RESULTS Q4/2015 & 2015 ESA TIHILÄ, CEO NICLAS ROSENLEW, CFO FEBRUARY 2, 2016 FINANCIAL RESULTS Q4/2015 & 2015 ESA TIHILÄ, CEO NICLAS ROSENLEW, CFO FEBRUARY 2, 2016 IMPORTANT NOTICE The following information contains, or may be deemed to contain, forward-looking statements. These

More information

Third quarter results FY2015. August 17, 2015

Third quarter results FY2015. August 17, 2015 Third quarter results FY2015 August 17, 2015 Disclaimer Stabilus S.A. (the Company, later Stabilus ) has prepared this presentation solely for your information. It should not be treated as giving investment

More information

Repligen Reports Third Quarter 2015 Financial Results

Repligen Reports Third Quarter 2015 Financial Results Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2015 Financial Results - Product Sales Increase 31% to $19.8 Million - - Conference

More information

Company Presentation June 2011 Biotest AG 0

Company Presentation June 2011 Biotest AG 0 Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and

More information

Financial Information

Financial Information Financial Information Solid results with in all key financial metrics of 23.6 bn, up 0.4% like-for like Adjusted EBITA margin up 0.3 pt on organic basis Net profit up +4% to 1.9 bn Record Free Cash Flow

More information

Midyear Presentation 2013. market strategy

Midyear Presentation 2013. market strategy Midyear Higher order Results intake, Presentation lower profitability 2013 focused market strategy THE SAFE HARBOR STATEMENT UNDER THE US PRIVATE SECURITIES LITIGATION REFORM ACT 1995 This presentation

More information

Merck Financial Report 1 st Quarter 2013

Merck Financial Report 1 st Quarter 2013 Merck Financial Report 1 st Quarter 2013 Financial Report 1 st Quarter 2013 2 Contents Interim Management Report as of March 31, 2013 03 The Merck Group 03 Highlights 07 Divisions 08 Merck Serono 13 Consumer

More information

1 st Quarter 2016 Conference Call Note

1 st Quarter 2016 Conference Call Note CREATING TOMORROW`S SOLUTIONS 1 st Quarter 2016 Conference Call Note Dr. Rudolf Staudigl (CEO), Dr. Tobias Ohler (CFO), April 28th, 2016 0 of 21 Disclaimer The information contained in this presentation

More information

H1 2012 I Düsseldorf, 10 August 2012. International Technology Group for Defence and Automotive

H1 2012 I Düsseldorf, 10 August 2012. International Technology Group for Defence and Automotive I Düsseldorf, 10 August 2012 International Technology Group for Defence and Automotive Rheinmetall Group Rheinmetall Group Key messages Sales increased by 9% Solid earnings: EBIT on previous year s level,

More information

Enhancing Value With Financial & Operational Excellence

Enhancing Value With Financial & Operational Excellence Enhancing Value With Financial & Operational Excellence Robert Hombach CFO & COO Enhancing Value With Financial & Operational Excellence Growing Sales & Earnings Generating value in attractive markets

More information

First Quarter 2015 Earnings Teleconference. April 28, 2015

First Quarter 2015 Earnings Teleconference. April 28, 2015 First Quarter 2015 Earnings Teleconference April 28, 2015 Introduction Chuck Triano Senior Vice President, Investor Relations Forward-Looking Statements and Non-GAAP Financial Information Our discussions

More information

Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO

Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO ENCORE 601 Phase 1b dose escalation has been completed and safety confirmation has commenced

More information

Q1 RESULTS 2015 30 APRIL 2015. Harald Wilhelm I Chief Financial Officer

Q1 RESULTS 2015 30 APRIL 2015. Harald Wilhelm I Chief Financial Officer 1 Q1 RESULTS 2015 30 APRIL 2015 Harald Wilhelm I Chief Financial Officer SAFE HARBOUR STATEMENT 2 Disclaimer This presentation includes forward-looking statements. Words such as anticipates, believes,

More information

Q2 and Half-Year 2010 Results

Q2 and Half-Year 2010 Results Q2 and Half-Year 2010 Results July 27, 2010 27.07.2010 1 Key financials in billions of Q2 2009 Q2 2010 Revenue 19.6 25.1 EBIT Net profit (loss) Earnings (loss) per share (in ) (1.0) (1.1) (0.99) 2.1 1.3

More information

9m RESULTS OCTOBER Harald Wilhelm I Chief Financial Officer

9m RESULTS OCTOBER Harald Wilhelm I Chief Financial Officer 1 9m RESULTS 2015 30 OCTOBER 2015 Harald Wilhelm I Chief Financial Officer SAFE HARBOUR STATEMENT 2 Disclaimer This presentation includes forward-looking statements. Words such as anticipates, believes,

More information

Europe: Growth of +7.8% in Recurring Operating Income France: New half of improved profitability

Europe: Growth of +7.8% in Recurring Operating Income France: New half of improved profitability 2014 FIRST HALF RESULTS: CONTINUED GROWTH Organic sales growth of 4.3% Increase in Recurring Operating Income of +13.8% Strong increase in adjusted net income, Group share of +16.7% Strong profit growth

More information

Regal Beloit Corporation Third Quarter 2014 Earnings Conference Call

Regal Beloit Corporation Third Quarter 2014 Earnings Conference Call Regal Beloit Corporation Third Quarter 2014 Earnings Conference Call November 4, 2014 Mark Gliebe Chairman and Chief Executive Officer Jon Schlemmer Chief Operating Officer Chuck Hinrichs Vice President

More information

Net Revenues Increased 120% to $17.1 Million from $7.8 Million in the Third Quarter of 2010

Net Revenues Increased 120% to $17.1 Million from $7.8 Million in the Third Quarter of 2010 Pernix Therapeutics Holdings Reports Third Quarter 2011 Financial Results November 15, 2011 12:55 PM ET Net Revenues Increased 120% to $17.1 Million from $7.8 Million in the Third Quarter of 2010 Strong

More information

Company Presentation VTG AG Connecting worlds. Analyst Conference April 14, 2015

Company Presentation VTG AG Connecting worlds. Analyst Conference April 14, 2015 Company Presentation VTG AG Connecting worlds Analyst Conference April 14, 2015 Table of content 1 Highlights 2014 2 Performance & Financials 2014 3 Update on Strategy 4 Outlook 2015 5 Appendix 1 Executive

More information

Half year results 2011

Half year results 2011 Half year results 2011 29 July 2011 Bert De Graeve, Chief Executive Officer Bruno Humblet, Chief Financial Officer Address by Bert De Graeve, Chief Executive Officer Introductory remark The consolidated

More information

Building on Leading Market Positions

Building on Leading Market Positions Building on Leading Market Positions Bharat Tewarie Head of Global Business Franchise Neurodegenerative Diseases Darmstadt, May 15, 2012 Agenda 1. Introduction 2. Rebif: Defending the franchise 3. Fertility:

More information

Conference Call Q3-2015/2016 GEROLD LINZBACH, CEO I DIRK KALIEBE, CFO. February 10, 2016 ON THE RIGHT TRACK

Conference Call Q3-2015/2016 GEROLD LINZBACH, CEO I DIRK KALIEBE, CFO. February 10, 2016 ON THE RIGHT TRACK Conference Call Q3-2015/2016 GEROLD LINZBACH, CEO I DIRK KALIEBE, CFO February 10, 2016 ON THE RIGHT TRACK On the right track Heidelberg is on track - the improvement in results due to the strategic realignment

More information

Q1 Fiscal Year 2016 Earnings Conference Call

Q1 Fiscal Year 2016 Earnings Conference Call NASDAQ: CMCO Q1 Fiscal Year 2016 Earnings Conference Call July 31, 2015 Timothy T. Tevens President & Chief Executive Officer Gregory P. Rustowicz Vice President - Finance & Chief Financial Officer 2015

More information

Lonza Reports Record First Quarter

Lonza Reports Record First Quarter Pharma&Biotech Lonza Reports Record First Quarter Q1 2016 Qualitative Business Update 26 April 2016 Richard Ridinger CEO Lonza Additional Information and Disclaimer Lonza Group Ltd has its headquarters

More information

Second Quarter 2015 Investor Conference Call

Second Quarter 2015 Investor Conference Call Second Quarter 2015 Investor Conference Call August 20, 2015 December 13, 2012 DRAFT 5 Safe Harbor Basis of Presentation Unless otherwise noted or unless the context otherwise requires, all references

More information

Health Care Worldwide. Citi - European Credit Conference September 24, 2015 - London

Health Care Worldwide. Citi - European Credit Conference September 24, 2015 - London Health Care Worldwide Citi - European Credit Conference September 24, 2015 - London Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties.

More information

Earnings Release Q4 FY 2015 July 1 to September 30, 2015

Earnings Release Q4 FY 2015 July 1 to September 30, 2015 Munich, Germany, November 12, 2015 Earnings Release FY 2015 July 1 to September 30, 2015 Strong finish for fiscal 2015»We delivered what we promised, and are well positioned to deliver on our plans for

More information

FOSSIL GROUP, INC. REPORTS FOURTH QUARTER AND FISCAL YEAR 2014 RESULTS; Fourth Quarter Net Sales of $1.065 Billion; Diluted EPS Increases 12% to $3.

FOSSIL GROUP, INC. REPORTS FOURTH QUARTER AND FISCAL YEAR 2014 RESULTS; Fourth Quarter Net Sales of $1.065 Billion; Diluted EPS Increases 12% to $3. FOSSIL GROUP, INC. REPORTS FOURTH QUARTER AND FISCAL YEAR 2014 RESULTS; Fourth Quarter Net Sales of $1.065 Billion; Diluted EPS Increases 12% to $3.00 Fiscal Year 2014 Net Sales Increase 8% to $3.510 Billion;

More information

First Quarter 2015 Earnings Conference Call. 20 February 2015

First Quarter 2015 Earnings Conference Call. 20 February 2015 First Quarter 2015 Earnings Conference Call 20 February 2015 Safe Harbor Statement & Disclosures The earnings call and accompanying material include forward-looking comments and information concerning

More information

Illumina, Inc. (Exact name of registrant as specified in its charter)

Illumina, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

2013 Second Quarter Review July 26, 2013 1

2013 Second Quarter Review July 26, 2013 1 213 Second Quarter Review July 26, 213 1 Panalpina Group Basel, July 26, 213 213 Second Quarter Review 213 Second Quarter Review July 26, 213 2 Highlights and key figures Operating and financial review

More information

Full Year Results 2011

Full Year Results 2011 Full Year Results 2011 Geoffrey McDonough (CEO) and Lars Sandström (CFO) Stockholm, 23 February, 2012 Who We Are Sobi is an innovative bio-pharmaceutical company with a leading position in the commercialization

More information

Third Quarter 2015 Earnings Conference Call. 21 August 2015

Third Quarter 2015 Earnings Conference Call. 21 August 2015 Third Quarter 2015 Earnings Conference Call 21 August 2015 Safe Harbor Statement & Disclosures The earnings call and accompanying material include forward-looking comments and information concerning the

More information

Reed Elsevier Results 2013 Erik Engstrom, CEO Duncan Palmer, CFO

Reed Elsevier Results 2013 Erik Engstrom, CEO Duncan Palmer, CFO Reed Elsevier Results Erik Engstrom, CEO Duncan Palmer, CFO FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the US Securities Act of

More information

Deutsche Bank 17th Annual European Leveraged Finance Conference. June 14, 2013 London

Deutsche Bank 17th Annual European Leveraged Finance Conference. June 14, 2013 London Deutsche Bank 17th Annual European Leveraged Finance Conference June 14, 2013 London Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A

More information

Q1 2014 Earnings Call. April 30 th, 2014

Q1 2014 Earnings Call. April 30 th, 2014 Q1 2014 Earnings Call April 30 th, 2014 Agenda Executive summary Financial data Outlook 2014 Appendix 2 Summary Q1 2014 (1) Revenue growth factors Positive start in FY 2014 with Q1 revenue increase of

More information

CONFERENCE CALL PRELIMINARY FIGURES FISCAL YEAR 2013

CONFERENCE CALL PRELIMINARY FIGURES FISCAL YEAR 2013 WELCOME DÜRR AKTIENGESELLSCHAFT CONFERENCE CALL PRELIMINARY FIGURES FISCAL YEAR 2013 Ralf W. Dieter, CEO Ralph Heuwing, CFO Bietigheim-Bissingen, February 25, 2014 www.durr.com DISCLAIMER This presentation

More information

ITW Conference Call Third Quarter 2013

ITW Conference Call Third Quarter 2013 ITW Conference Call Third Quarter 2013 October 22, 2013 SOLID GROWTH. STRONG RETURNS. BEST-IN-CLASS OPERATOR. Forward-Looking Statements Safe Harbor Statement This conference call contains forward-looking

More information

Novartis: transforming our company for the future market

Novartis: transforming our company for the future market Novartis: transforming our company for the future market Joe Jimenez CEO Novartis JP Morgan Conference San Francisco January 12, 2015 Disclaimer This presentation contains forward-looking statements that

More information

Preliminary results FY2015. November 27, 2015

Preliminary results FY2015. November 27, 2015 Preliminary results FY2015 November 27, 2015 Disclaimer Stabilus S.A. (the Company, later Stabilus ) has prepared this presentation solely for your information. It should not be treated as giving investment

More information

Earnings Release Q2 FY 2015 January 1 to March 31, 2015

Earnings Release Q2 FY 2015 January 1 to March 31, 2015 Munich, Germany, May 7, 2015 Earnings Release FY 2015 January 1 to March 31, 2015 Portfolio gains drive income»for business volume, we performed well in our markets. The profitability of our Industrial

More information

Design the future. Second quarter results 2015. Detlef Borghardt, CEO Wilfried Trepels, CFO. August 06, 2015

Design the future. Second quarter results 2015. Detlef Borghardt, CEO Wilfried Trepels, CFO. August 06, 2015 Design the future Second quarter results 215 Detlef Borghardt, CEO Wilfried Trepels, CFO August 6, 215 Agenda 1 Market Development 3 2 Financial information 5 3 Outlook 17 2 Truck and trailer market development

More information

The Sherwin-Williams Company Reports 2016 First Quarter Financial Results

The Sherwin-Williams Company Reports 2016 First Quarter Financial Results The Sherwin-Williams Company Reports 2016 First Quarter Financial Results First quarter consolidated net sales increased 5.1% to a record $2.57 billion; Net sales from stores open more than twelve calendar

More information

Q4 & Full Year 2015 Earnings Call Investor Slides. February 11, 2016

Q4 & Full Year 2015 Earnings Call Investor Slides. February 11, 2016 Q4 & Full Year Earnings Call Investor Slides February 11, 2016 Non-GAAP Disclaimer The financial results disclosed in this presentation include certain measures calculated and presented in accordance with

More information

Press release March 5, 2015

Press release March 5, 2015 2014 FULL YEAR RESULTS: GROWTH MOMENTUM CONFIRMED Acceleration of organic sales growth Further growth in Recurring Operating Income, up by +10.6% Net income from continuing operations up by +24.6% Increase

More information

Full-year results 2014. December 02, 2014

Full-year results 2014. December 02, 2014 Full-year results 2014 December 02, 2014 Disclaimer Stabilus S.A. (the Company, later Stabilus ) has prepared this presentation solely for your information. It should not be treated as giving investment

More information

2013 Third Quarter Review October 25, 2013 1

2013 Third Quarter Review October 25, 2013 1 October 25, 213 1 Panalpina Group October 25, 213 213 Third Quarter Review October 25, 213 2 Highlights and key figures Operating and financial review Outlook Growth in profitability and margins in the

More information

Q3/2015 Results Analyst and Investor Conference Call. 29 October 2015

Q3/2015 Results Analyst and Investor Conference Call. 29 October 2015 Q3/2015 Results Analyst and Investor Conference Call 29 October 2015 Deutsche Börse Group 1 Highlights Q3/2015 Results Presentation Index derivatives and cash equities benefitted from higher volatility;

More information

This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private

This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private Safe Harbour Statement This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995). By their nature, forward-looking

More information

Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights. October 27, 2015

Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights. October 27, 2015 Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights October 27, 2015 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA This presentation of Merck & Co., Inc.,

More information

Second Quarter 2007 Results. July 31, 2007

Second Quarter 2007 Results. July 31, 2007 Second Quarter 2007 Results July 31, 2007 Safe Harbor For Forward Looking Statements Except for historical information, all other information in this presentation consists of forward-looking statements

More information

3 rd Quarter 2014 Earnings Conference Call Transcript

3 rd Quarter 2014 Earnings Conference Call Transcript 3 rd Quarter 2014 Earnings Conference Call Transcript Overview*: BDC reported 3Q14 consolidated revenues of $613.1M, income from continuing operations of $50.4M and diluted EPS from continuing operations

More information

GrandVision reports Revenue growth of 13.8% and EPS growth of 31.7%

GrandVision reports Revenue growth of 13.8% and EPS growth of 31.7% GrandVision reports Revenue of 13.8% and EPS of 31.7% Schiphol, the Netherlands 16 March 2015. GrandVision NV (EURONEXT: GVNV) publishes Full Year and Fourth Quarter 2015 results. 2015 Highlights Revenue

More information

Quality Affordable Healthcare Products. Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company July 31, 2013

Quality Affordable Healthcare Products. Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company July 31, 2013 Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company July 31, 2013 Important Information For Investors And Shareholders This announcement does not constitute an offer to sell, or

More information

Regal Beloit Corporation Fourth Quarter 2014 Earnings Conference Call

Regal Beloit Corporation Fourth Quarter 2014 Earnings Conference Call Regal Beloit Corporation Fourth Quarter 2014 Earnings Conference Call February 17, 2015 Mark Gliebe Chairman and Chief Executive Officer Jon Schlemmer Chief Operating Officer Chuck Hinrichs Vice President

More information

2012 Full-year results

2012 Full-year results 2012 Full-year results Analysts & Media Conference Basel, 21 February 2013 Disclaimer This presentation contains certain forward-looking statements, which can be identified by the use of terminology such

More information

Bertelsmann Annual Results 2010 Investor Conference Call

Bertelsmann Annual Results 2010 Investor Conference Call Bertelsmann Annual Results 2010 Investor Conference Call March 29, 2011 Dr. Thomas Rabe Member of the Executive Board and Chief Financial Officer Bertelsmann AG Summary and highlights Operating performance

More information

Software AG Results 1 st Quarter 2015 (IFRS, unaudited)

Software AG Results 1 st Quarter 2015 (IFRS, unaudited) Software AG Results 1 st Quarter (IFRS, unaudited) April 29, 1 Safe Harbor This presentation includes forward-looking statements based on the beliefs of Software AG management. Such statements reflect

More information

Fiscal Year Guidance Achieved Execution of Vision 2020 Begun

Fiscal Year Guidance Achieved Execution of Vision 2020 Begun Fiscal Year Guidance Achieved Execution of Vision 2020 Begun Joe Kaeser, President and Chief Executive Officer of Siemens AG We delivered the results we originally promised for fiscal 2014 and made substantial

More information

J.P. MORGAN HIGH YIELD & LEVERAGED FINANCE CONFERENCE FEBRUARY 24, 2015

J.P. MORGAN HIGH YIELD & LEVERAGED FINANCE CONFERENCE FEBRUARY 24, 2015 J.P. MORGAN HIGH YIELD & LEVERAGED FINANCE CONFERENCE FEBRUARY 24, 2015 DISCLAIMER This presentation contains, in addition to historical information, certain forward-looking statements within the meaning

More information

THIRD QUARTER FINANCIAL RESULTS

THIRD QUARTER FINANCIAL RESULTS Kellogg Company THIRD QUARTER FINANCIAL RESULTS Forward Looking Statements This presentation contains, or incorporates by reference, forward looking statements with projections concerning, among other

More information

Second Half and Full Year 2011/2012 Consolidated Results

Second Half and Full Year 2011/2012 Consolidated Results Second Half and Full Year 2011/2012 Consolidated Results Unaudited preliminary data Ongoing audit process Approved by the Board of Directors on May 8, 2012 Actual Current Operating Income (COI) in line

More information

Annual Report 2008. Staying the course

Annual Report 2008. Staying the course Annual Report 2008 Staying the course More information inside the cover: Business sectors and divisions Merck 2008 at a glance Major achievements of 2008 Despite a rapidly deteriorating economic situation,

More information

1Q15 Earnings Release. April 29 th 2015 LG Electronics

1Q15 Earnings Release. April 29 th 2015 LG Electronics 1Q15 Earnings Release April 29 th 2015 LG Electronics All information regarding management performance and financial results of LG Electronics (the Company ) during the 1 st quarter of 2015 as contained

More information

Full Year Results 2012. Conference Call Presentation, 21 st March 2013

Full Year Results 2012. Conference Call Presentation, 21 st March 2013 Full Year Results 2012 Conference Call Presentation, 21 st March 2013 0 Disclaimer This presentation may contain forward-looking statements based on current assumptionsandforecastsmadebybrenntag AG and

More information

Flamel Technologies Provides Update on Corporate Progress

Flamel Technologies Provides Update on Corporate Progress Flamel Technologies Provides Update on Corporate Progress Clinical Programs Continue to Move Forward Outlines Full Year 2016 Revenue Guidance Lyon, France January 8, 2016 - Flamel Technologies (NASDAQ:

More information

Fiscal Year 2015 Fourth Quarter Conference Call

Fiscal Year 2015 Fourth Quarter Conference Call Copyright 2015 Rockwell Automation, Inc. All rights reserved. Fiscal Year 2015 Fourth Quarter Conference Call November 10, 2015 Copyright 2015 Rockwell Automation, Inc. All rights reserved. 2 Safe Harbor

More information

Fiscal Year 2015 Third Quarter Conference Call

Fiscal Year 2015 Third Quarter Conference Call Fiscal Year 2015 Third Quarter Conference Call July 29, 2015 Copyright 2015 Rockwell Automation, Inc. All Rights Reserved. 2 Safe Harbor Statement This presentation includes statements related to the expected

More information

Interim Report Q1 2008

Interim Report Q1 2008 Interim Report Q1 Contents 3 Interim Management Report of the Merck Group as of March 31, 3 At a glance Highlights 4 Merck Group 7 Merck shares 8 Business sectors 9 Divisions 9 Merck Serono 11 Consumer

More information

Third Quarter 2015 Conference Call

Third Quarter 2015 Conference Call Third Quarter 2015 Conference Call E. Scott Santi, Chairman & CEO Michael M. Larsen, Senior Vice President & CFO Aaron H. Hoffman, Vice President, Investor Relations October 21, 2015 Forward Looking Statements

More information

Drägerwerk AG & Co. KGaA Analyst Conference 2015. Frankfurt, March 11, 2015

Drägerwerk AG & Co. KGaA Analyst Conference 2015. Frankfurt, March 11, 2015 Drägerwerk AG & Co. KGaA Analyst Conference 2015 Frankfurt, March 11, 2015 Disclaimer This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase any

More information

Q3 2013 Financial Highlights. October 16, 2013

Q3 2013 Financial Highlights. October 16, 2013 October 16, 2013 This presentation contains non-gaap measures relating to the company's performance. You can find the reconciliation of these measures to the nearest comparable GAAP measures in the appendix

More information

The world leader in photodynamic technology

The world leader in photodynamic technology Brilliance in photodynamic technology TM The world leader in photodynamic technology Presentation of third quarter 2010 results 27 October 2010 Kjetil Hestdal, President & CEO Christian Fekete, CFO The

More information

Full Year 2015 Results

Full Year 2015 Results Full Year 2015 Results 16 March 2016 Conference call on FY 2015 results Corporate Finance & Investor Relations AGENDA FY 2015 results presentation Highlights 2015 Financials 2015 Outlook 2016 Appendix

More information

EDWARDS LIFESCIENCES REPORTS STRONG FIRST QUARTER RESULTS DRIVEN BY SALES GROWTH OF 18.8 PERCENT

EDWARDS LIFESCIENCES REPORTS STRONG FIRST QUARTER RESULTS DRIVEN BY SALES GROWTH OF 18.8 PERCENT Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Amanda C. Fowler, 949-250-5070 Investor

More information

Q3 2015 Financial Results and Corporate Update. November 4, 2015

Q3 2015 Financial Results and Corporate Update. November 4, 2015 Q3 2015 Financial Results and Corporate Update November 4, 2015 Introductions and Forward- Looking Statements Silvia Taylor, SVP Investor Relations and Corporate Affairs Agenda Introductions and Forward-Looking

More information

Ontex Q3 2015: Trading in line with Company expectations and full year outlook reiterated

Ontex Q3 2015: Trading in line with Company expectations and full year outlook reiterated Ontex Q3 2015: Trading in line with Company expectations and full year outlook reiterated Aalst-Erembodegem, November 5, 2015 - Ontex Group NV (Euronext Brussels: ONTEX; Ontex, the Group or the Company

More information

FURTHER PROFIT GROWTH IN FIRST-HALF 2015

FURTHER PROFIT GROWTH IN FIRST-HALF 2015 FURTHER PROFIT GROWTH IN FIRST-HALF 2015 Net sales of 37.7bn, up +5.2% (+2.9% on an organic basis) Growth in Recurring Operating Income: 726m, +2.6% at constant rates Strong growth in adjusted net income,

More information

Interim financial report third quarter 2014 Investor presentation. Koen Van Gerven, CEO Pierre Winand, CFO

Interim financial report third quarter 2014 Investor presentation. Koen Van Gerven, CEO Pierre Winand, CFO Interim financial report third quarter 204 Investor presentation Koen Van Gerven, CEO Pierre Winand, CFO Brussels November, 4th 204 Investor presentation - Interim financial report 3Q4 2 Financial Calendar

More information

Annual Report on Form 20-F

Annual Report on Form 20-F Annual Report on Form 20-F 2 Teva at a Glance Founded in 1901 by three young pharmacists, today Teva Pharmaceutical Industries Ltd. is a leader in the global pharmaceutical industry, providing medicines

More information

Q3 and January-September 2014 Results

Q3 and January-September 2014 Results Q3 and January-September 2014 Results Bodo Uebber Member of the Board of Management Finance & Controlling and Daimler Financial Services October 23, 2014 1 2 Contents Results for Q3 2014 Outlook for 2014

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group Commerzbank German Investment Seminar January 11/12, 2016 For detailed financial information please see our annual/quarterly reports and/or conference call materials

More information

Conference Call Q1-2015/2016

Conference Call Q1-2015/2016 Conference Call Q1-2015/2016 DIRK KALIEBE August 12, 2015 Highlights Q1-2015/2016 Strategic reorientation is taking effect Good order situation, improved backlog Strong revenue growth due to solid order

More information

Fourth Quarter 2015 Earnings Conference Call

Fourth Quarter 2015 Earnings Conference Call Earnings Conference Call November 3, 2015 Safe Harbor Statement Our commentary and responses to your questions may contain forward-looking statements, including our outlook for the remainder of the year,

More information

2015 Second Quarter Business Review (unaudited) July 23, 2015

2015 Second Quarter Business Review (unaudited) July 23, 2015 2015 Second Quarter Business Review (unaudited) July 23, 2015 1 Forward Looking Statement This presentation contains forward-looking information about 3M's financial results and estimates and business

More information

Adoption of Business Net Income

Adoption of Business Net Income Adoption of Business Net Income 1 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking

More information